TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05422404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Reflux Mucosectomy
Description: ARMS will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. The upper gastrointestinal tract will be evaluated in detail first. Then Endoscopic mucosal resection(EMR) will performed at E-C junction, gastric cardia side. About 50%-70% of the EGJ circumference will be resected to create artificial ulcer which will lead to mucosal contraction during the healing process.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-reflux mucosal ablation
Description: ARMA will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. Mucosal ablation will be performed in retroflex fashion following. Then APC with soft coagulation(effect 2, 40W) will be used to mark the area that not going to be ablated at gastric carida over the great curvature direction, about 1.5 scope width. Then submucosa injection with saline and indigo carmine dye will be performed using a 25 guage needle.
Study: NCT05956639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-month course of antiandrogen drugs
Description: 6-month course of Rezvilutamide and ADT + chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-term course of antiandrogen drugs
Description: Long-term course of Rezvilutamide and ADT + chemotherapy
Study: NCT05682391

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed rest
Description: Strict bed rest ordered after surgery that does not allow the participant to elevate the head of bed over 30 degrees

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed rest
Description: Strict bed rest ordered after surgery that does not allow the participant to elevate the head of bed over 30 degrees
Study: NCT06037915

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low flow oxygen with nasopharyngeal tube
Description: low flow oxygen with nasopharyngeal tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow oxygen with OptiflowTM Nasal High Flow
Description: high flow oxygen with OptiflowTM Nasal High Flow
Study: NCT06033066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Small financial incentive or prize incentive

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Small financial incentive or prize incentive

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Message
Description: Message inviting participant to enroll
Study: NCT06237582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epigastric lymph node biopsy
Description: epigastric lymph node biopsy and analysis to evaluate rate dissemination of ovarian carcinomatosis by this way
Study: NCT04277559

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient preferential music
Description: Patients will listen to their preferred music through the headphones before surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical music
Description: Patients will listen to classical music through headphones before surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No music
Description: Patients will not listen to music.
Study: NCT05581602

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearing bracelets (3-Axis Logging Accelerometer)
Description: Participants will be required to wear wristbands containing an accelerometer on each wrist. The bracelets will be kept on both wrists for 7 days with permission to remove them from time to time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing bracelets (3-Axis Logging Accelerometer)
Description: Participants will be required to wear wristbands containing an accelerometer on each wrist. The bracelets will be kept on both wrists for 7 days with permission to remove them from time to time.
Study: NCT05062122

Intervention type: OTHER
Intervention: vibration group
Description: Hand skills were evaluated before and after 10 minutes of vibration application.

Intervention type: OTHER
Intervention: kinesiology tape group
Description: Dexterity was assessed before and after kinesiology tape application.

Intervention type: OTHER
Intervention: control group
Description: Manual dexterity was assessed before and after traditional physiotherapy.
Study: NCT06211439

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real transcranial alternating current stimulation
Description: The alternating current was non-invasively delivered using an M×N five-channel high-definition transcranial electrical current stimulator (Soterix Medical). A BrainCap (Brain Vision) embedded with high-definition plastic holders consisted of five 12-mm-diameter Ag/AgCl ring electrodes, filled with conductive gel. During real HD-tACS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial alternating current stimulation
Description: For the sham condition(sham HD-tACS), the same electrode placement was used as in the stimulation condition, but the current was only applied during the first and last 30 seconds of the entire 20-minute stimulation period.
Study: NCT05254665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel Polymeric Micelles for Injection
Description: Docetaxel polymeric micelles，usage and quantity of Docetaxel polymeric micelles follows the clinical study proctol，not published.
Study: NCT05914948

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic 8-contact Vectris subcompact or compact electrode.
Description: Subjects meeting study eligibility criteria will be implanted with a Medtronic 8-contact Vectris subcompact or compact electrode.
Study: NCT05347043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montreal cognitive assessment
Description: Montreal cognitive assessment and standardized neuropsychological evaluation (Test of Attentional Performance of Zimmermann and Fimm ; Wechsler Adult Intelligence Scale 4th version digit span ; Wechsler memory scale III, spatial span ; Wisconsin Card Scoring Test, GREFEX version ; Wechsler Adult Intelligence Scale 4th version block design ; Six elements test GREFEX version; free and cued selective reminding test, 16 items, B version ; Behavioral Rating Inventory of Executive Function ; Modified Fatigue Impact Scale)
Study: NCT06078865

Intervention type: DEVICE
Intervention: FX Artificial Shoulder Prosthesis
Description: Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System,Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
Study: NCT04253080

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Blood sample before treatment, 3 months after treatment and after 1 year or relapse or resumption of disease progression.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cutaneous melanoma biopsy
Description: Cutaneous melanoma biopsy before treatment, 3 months after treatment and relapse or resumption of disease progression.
Study: NCT05497401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MesenCure
Description: Enhanced mesenchymal cell-based product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT05074797

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory
Description: laboratory data

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory
Description: laboratory data

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory
Description: laboratory data
Study: NCT05111860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab+mFOLFOX6
Description: Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
Study: NCT04554420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Participatory Action Research-Mental Health Curriculum
Description: The mental health curriculum will focus on enhancing the knowledge, critical consciousness (i.e., exploration of systemic/racial problems), research self-efficacy, and other skills of youth to integrate their lived experiences and identity to learning about the intersection of system and community level issues in mental health. Activities will center on participatory action approaches to engaging youth in culturally/community responsive ways.
Study: NCT05477615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: - Lazertinib 240mg (3 tablets, 80mg/1tablet) once a day, oral, before disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: - Pemetrexed 500mg/m2 is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: - Carboplatin AUC x 5 mg/mL.min is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
Study: NCT05723224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: elective endoscopic gallbladder treatment
Description: Access to the gallbladder will be performed from the stomach or duodenum using LAMS with electrocautery-enhanced delivery system such as Hot Axios, Boston Scientifics device or Hot Spaxus, Taewoong at the discretion of the endoscopist. A stent of 10 mm in diameter will be used if the largest gallstone will be smaller than 10 mm in size while greater diameter (≥15 mm stent) will be used if the largest gallstone will be larger than 10mm. Colecystoscopy lithotripsy will be performed, when needed, using mechanical lithotripsy and/or laser lithotripsy at the discretion of the endoscopist. First cholecystoscopy will be done 2 weeks after the index procedure
Study: NCT05404243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenolization
Description: In case of phenolization group, an Abbocath catheter 18 G is introduced into the cystic cavity. Undiluted 88% phenol is instilled into the cavity, ensuring that the cystic cavity is filled. It is maintained for 5 min until complete coagulation of the cyst is achieved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery
Description: In case of conventional surgery, entire exeresis is performed by means of an electric scalpel
Study: NCT05472038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b5 Bivalent (WT/OMI BA.2)
Description: BNT162b5 Wild Type and BNT162b5 OMICRON \[B.1.1.529 sublineage BA.2\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (WT/OMI BA.1)
Description: BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.1\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (WT/OMI BA.4/BA.5)
Description: BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (WT/OMI BA.4/BA.5)
Description: BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (WT/OMI BA.4/BA.5)
Description: BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (WT/OMI BA.4/BA.5)
Description: BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (WT/OMI BA.4/BA.5)
Description: BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (WT/OMI BA.4/BA.5)
Description: BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (WT/OMI BA.4/BA.5)
Description: BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 Bivalent (WT/OMI BA.4/BA.5)
Description: BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
Study: NCT06445829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: adding 300mg magnesium sulfate into cocktail injection
Study: NCT04910607

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire with 4 axes:~sociological, reflexive medical, prospective medical, transversal

Intervention type: OTHER
Intervention: Interview
Description: Interview concerning health pathways, experience of confinement, consequences of confinement on health, representations of obesity.

Intervention type: OTHER
Intervention: Interview
Description: Interview concerning health pathways, experience of confinement, consequences of confinement on health, representations of obesity.
Study: NCT05472038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b5 Bivalent (Original/OMI BA.4/BA.5)
Description: BNT162b5 Wild Type and BNT162b5 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b6 Bivalent (Original/OMI BA.4/BA.5)
Description: BNT162b6 Wild Type and BNT162b6 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b7 Bivalent (Original/OMI BA.4/BA.5)
Description: BNT162b7 Wild Type and BNT162b7 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b7 Monovalent (OMI BA.4/BA.5)
Description: BNT162b7 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
Study: NCT05084313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: This group of patients will receive manual therapy techniques to harmonize vegetative nervous system. PPG and GSR will be recorded during the intervention. The techniques consist of CV-4 technique, suboccipital decompression, lumbo-sacral decompression, release of the transverse diaphragms, frontal lift technique, parietal lift technique, temporal techniques, temporo-mandibular joint myofascial release, deep cervical fasciae technique as described in Upledger's protocol. In addition to the protocol; rib raising technique, larynx and sternocleidomastoid muscle fascial release and occipito-mastoid suture release will be applied. All intervention is planned to take approximately 20 minutes. The group will include forty healthy individuals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep-slow breathing
Description: Patients in this group will do slow paced breathing to increase heart rate variability as it can be partially modulated by respiratory effects. The patients will be able to cease the session in case of feeling uncomfortable. The main purpose will be that the individuals should breathe six breaths per minute to increase respiratory sinus arrhythmia which is also reflected at PPG waveforms and in reduction in GSR. The group will include forty healthy individuals.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Control group patients will be attached to the sensors, and they will rest in a quiet and controlled indoor environment without any intervention. The aim of including this group is to to understand whether the parasympathetic effects expected in the manual therapy group were due to the intervention. The group will include forty healthy individuals.
Study: NCT05822934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin-Gemcitabine Cisplatin-Gemcitabine
Description: Carboplatin-gemcitabine versus cisplatin-gemcitabine as neoadjuvant chemotherapy for treatment of muscle invasive urinary bladder cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin-Gemcitabine Cisplatin-Gemcitabine
Description: Carboplatin-gemcitabine versus cisplatin-gemcitabine as neoadjuvant chemotherapy for treatment of muscle invasive urinary bladder cancer
Study: NCT05279352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FBR-002
Description: Administration on D1 and D3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration on D1 and D3
Study: NCT05835765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Elastometric Body in Preterm Newborns
Description: The study group made up of 12 newborns will use Flexa bodysuits made to the measurements of newborns.The bodysuit will be worn for a minimum of 4 hours and a maximum of 6 hours each day for a week (depending on any signs of discomfort). After 6 hours, the body will be removed and reapplied the next day for 4-6 hours. The child will use the same leotard for the entire study period (1 week) and changed only if dirty.
Study: NCT05952232

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PA-GH-01
Description: 1 capsule after breakfast once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MK-GH-04
Description: 1 capsule after breakfast once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TSH-GH-03
Description: 1 capsule after breakfast once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PA-GH-02
Description: 1 capsule after breakfast once a day
Study: NCT04903782

Intervention type: DIAGNOSTIC_TEST
Intervention: Family-based whole genome sequencing
Description: 1. Germline whole-genome family-based sequencing and variant identification.~2. Multidisciplinary Meeting case discussion.~3. Recommendation of referral to a Cancer Genetics Clinic for further investigation, follow up and/or genetic counselling.~4. Psychosocial study to analyse the impact of germline sequencing on families.
Study: NCT05041231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBT)
Description: Any invasive procedures will be done. The treatment in question will be done by a device that looks like a bracelet, which is placed on the hand/fingers to emit light/laser and does not cause pain or temperature change. There will be 8 photobiomodulation sessions, 2 per week, 10 minutes each session.~The dosimetric parameters of the therapy will be carried out in a standardized and personalized way, with programming of the light and all the necessary information so that the device can carry out the application of the treatment application of electromagnetic waves in the red and infrared spectral range 660-1000 nm).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Photobiomodulation therapy (Sham PBT)
Description: Similar to active PBT, however, the device will not provide the active electromagnetic waves)
Study: NCT04396366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active drug
Description: QBW251 Capsule 300mg Oral use, one capsule twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule 300mg Oral use, one capsule twice daily.
Study: NCT05968677

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FSMP
Description: Food for Special Medical Purposes specifically formulated for the dietary management of malnourished patients following therapeutic treatments such as chemo and radiotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional counseling
Description: Participant's nutritional status will be evaluated, anthropometric data will be collected (weight, height, BMI), body composition will be evaluated (FFMI, BIVA) and a food diary will be compiled

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Participant's nutritional status will be evaluated, anthropometric data will be collected (weight, height, BMI), body composition will be evaluated (FFMI, BIVA) and a food diary will be compiled
Study: NCT06143358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qingkepingchuan Granules
Description: Qingkepingchuan Granules,Take it three times a day with water after meals.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: Oxygen intake, selection of appropriate antibiotics based on lab results, and other treatments
Study: NCT05710055

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study product A (Wonderlab wonder4shape)
Description: Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study product B (Wonderlab wonder4shape)
Description: Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study product C (Wonderlab wonder4shape)
Description: Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Study product D
Description: Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
Study: NCT05392608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib 150 MG Oral Tablet [Piqray]
Description: Alpelisib 300mg once daily (may be reduced to 1dd250 or 1dd200mg in case of toxicity)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 300mg 1x/four weeks
Study: NCT05963490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Regorafenib 120 mg orally once daily on days 1-21 of each 28 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg intravenously every 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: hypofractionated radiotherapy (5 fractions of 4-12Gy) and low-dose radiotherapy (5 fractions of 0.5-2Gy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib 80mg orally once daily on days 1-21 of each 28 days cycle.
Study: NCT05336812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study: NCT04699890

Intervention type: OTHER
Intervention: Blood sampling, questionnaires and specific exams
Description: Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.

Intervention type: OTHER
Intervention: Blood sampling, questionnaires and specific exams
Description: Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.